Truqap is often a kinase inhibitor that works by blocking pathways that assist the cancer cells endure and mature, so cuts down cancer progress. Truqap is from a class of medicines termed an AKT inhibitor. Truqap acquired FDA acceptance on November 17, 2023, after favourable effects within the CAPIt